Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Schizophrenia-Like Dopamine Release Abnormalities in a Mouse Model of NMDA Receptor Hypofunction.

Nakao K, Jeevakumar V, Jiang SZ, Fujita Y, Diaz NB, Pretell Annan CA, Eskow Jaunarajs KL, Hashimoto K, Belforte JE, Nakazawa K.

Schizophr Bull. 2018 Jan 31. doi: 10.1093/schbul/sby003. [Epub ahead of print]


Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia.

Zimmerman CN, Eskow Jaunarajs KL, Meringolo M, Rizzo FR, Santoro M, Standaert DG, Pisani A.

Front Syst Neurosci. 2017 Jun 13;11:43. doi: 10.3389/fnsys.2017.00043. eCollection 2017.


Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.

Figge DA, Eskow Jaunarajs KL, Standaert DG.

J Neurosci. 2016 Jun 15;36(24):6514-24. doi: 10.1523/JNEUROSCI.0683-16.2016.


Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia.

Eskow Jaunarajs KL, Bonsi P, Chesselet MF, Standaert DG, Pisani A.

Prog Neurobiol. 2015 Apr;127-128:91-107. doi: 10.1016/j.pneurobio.2015.02.002. Epub 2015 Feb 17. Review.


Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.

Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C.

Brain Res. 2013 Nov 6;1537:327-39. doi: 10.1016/j.brainres.2013.09.020. Epub 2013 Sep 21.


Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW.

Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3.


Removing the blinkers: moving beyond striatal dopamine in Parkinson's disease.

Eskow Jaunarajs KL, Standaert DG.

J Neurochem. 2013 Jun;125(5):639-41. doi: 10.1111/jnc.12167. No abstract available.


Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Dupre KB, Ostock CY, George JA, Eskow Jaunarajs KL, Hueston CM, Bishop C.

ACS Chem Neurosci. 2013 May 15;4(5):747-60. doi: 10.1021/cn300234z. Epub 2013 Apr 1.


Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.

Bishop C, George JA, Buchta W, Goldenberg AA, Mohamed M, Dickinson SO, Eissa S, Eskow Jaunarajs KL.

Eur J Neurosci. 2012 Sep;36(6):2839-48. doi: 10.1111/j.1460-9568.2012.08202.x. Epub 2012 Jul 5.


L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.

Eskow Jaunarajs KL, George JA, Bishop C.

Neuroscience. 2012 Aug 30;218:243-56. doi: 10.1016/j.neuroscience.2012.05.052. Epub 2012 Jun 1.


Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.

Lindenbach D, Ostock CY, Eskow Jaunarajs KL, Dupre KB, Barnum CJ, Bhide N, Bishop C.

J Pharmacol Exp Ther. 2011 Jun;337(3):755-65. doi: 10.1124/jpet.111.179416. Epub 2011 Mar 14.


Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.

Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, Bishop C.

Exp Neurol. 2011 Jun;229(2):288-99. doi: 10.1016/j.expneurol.2011.02.012. Epub 2011 Feb 22.


Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.

Eskow Jaunarajs KL, Dupre KB, Ostock CY, Button T, Deak T, Bishop C.

Behav Pharmacol. 2010 Oct;21(7):627-37. doi: 10.1097/FBP.0b013e32833e7e80.


Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, Bishop C.

Neurosci Biobehav Rev. 2011 Jan;35(3):556-64. doi: 10.1016/j.neubiorev.2010.06.007. Epub 2010 Jul 6. Review.

Supplemental Content

Loading ...
Support Center